Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P312: Efficacy in biologic failure and non-biologic-failure populations in a Phase 3 study of ustekinumab in moderate–severe ulcerative colitis: UNIFI

ECCO '19 Copenhagen

Year: 2019
Authors:

B. E. Sands*1, L. Peyrin-Biroulet2, C. Marano3, C. D. O'Brien3, H. Zhang3, J. Johanns4, P. Szapary3, D. Rowbotham5,6, R. W. Leong7,8, R. P. Arasaradnam9, S. Danese10, G. Van Assche11, S. Targan12, W. J. Sandborn13

1Icahn School of Medicine at Mount Sinai, New York, USA, 2Nancy University Hospital, Université de Lorraine, Nancy, France, 3Janssen Research and Development, LLC, Spring House, USA, 4Janssen Research and Development, Spring House, USA, 5Auckland City Hospital, Auckland, New Zealand, 6University of Auckland, Auckland, New Zealand, 7Concord Hospital, Sydney, Australia, 8Macquarie University Hospital, Sydney, Australia, 9Warwick Medical School, University Hospital Coventry, Warwickshire, UK, 10Humanitas Research Hospital, Milan, Italy, 11University of Leuven, Leuven, Belgium, 12Cedars-Sinai Medical Center, Los Angeles, USA, 13University of California San Diego, La Jolla, USA

P313: Impact of upadacitinib on the general clinical condition of patients with Crohn’s disease (CD): data from the randomised CELEST study

ECCO '19 Copenhagen

Year: 2019
Authors:

E. V. Loftus Jr*1, D. T. Rubin2, J. Panes3, D. Pugatch4, W. Zhou4, S. Goteti4, A. Lacerda4, S. Travis5

1Mayo Clinic, Rochester, Minnesota, USA, 2The University of Chicago Medicine, Chicago, Illinois, USA, 3Hospital Clínic Barcelona, Barcelona, Spain, 4AbbVie Inc., North Chicago, Illinois, USA, 5Oxford University Hospitals, Oxford, UK

P314: Long-term fate of the excluded rectum in Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Yzet*1, G. Kassim2, N. Nair2, J-F. Colombel2, D. B. Sachar2

1Amiens university hospital, Amiens, France, 2Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, USA

P315: Systemic and tissue modulation of IL-23 pathway biomarkers in a Phase 2 study of risankizumab in patients with Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Salas*1, K. M. Grebe2, N. Powell3, J. Panés1, J. W. Davis4, F. Hong4, Y. Pang4, A. A. Suleiman5, K. Wallace4, B. G. Feagan6

1Hospital Clinic Barcelona, Barcelona, Spain, 2AbbVie Inc., Worcester MA, USA, 3Guy's and St Thomas' Hospital, London, UK, 4AbbVie Inc., Chicago, IL, USA, 5AbbVie Inc., Ludwigshafen am Rhein, Germany, 6University of Western Ontario, London, ON, Canada

P316: Transanal minimal invasive proctectomy (TaMIP) for perineal Crohn’s disease; a multi-centre prospective cohort study

ECCO '19 Copenhagen

Year: 2019
Authors:

P. Chandrasinghe*1,2,3, F. Di Candido4, J. Warusavitarne2,5, A. Spinelli4,6

1St Mark's Hospital, Department of Colorectal Surgery, London, UK, 2Imperial College London, Department of Surgery and Cancer, London, UK, 3University of Kelaniya, Department of Surgery, Kelaniya, Sri Lanka, 4Humanitas Clinical and Research Center, Division of Colon and Rectal Surgery, Milan, Italy, 5St Mark's Hospital, Department of Gastroenterology, London, UK, 6Humanitas University, Department of Biomedical Sciences, Milan, Italy

P317: Characterisation of patients with delayed response to ustekinumab for Crohn’s disease

ECCO '19 Copenhagen

Year: 2019
Authors:

B. E. Sands*1, A. Oortwijn2, N. Rijnders2, J. Izanec3, C. Gasink3, D. Jacobstein4, O. J. Adedokun4, T. Ma4, L-L. Gao4, J-F. Colombel5, S. Targan6, S. Ghosh7, W. J. Sandborn8

1Icahn School of Medicine at Mount Sinai, New York, USA, 2Janssen Biologics BV, Leiden, The Netherlands, 3Janssen Scientific Affairs, LLC, Horsham, USA, 4Janssen Research and Development, LLC, Spring House, USA, 5Icahn School of Medicine at Mt Sinai, New York, USA, 6Cedars-Sinai Medical Center, Los Angeles, USA, 7University of Birmingham, Birmingham, UK, 8University of California San Diego, La Jolla, USA

P318: Ustekinumab: early experience and medium-term outcomes from a UK multi-centre real-world cohort

ECCO '19 Copenhagen

Year: 2019
Authors:

R. Gadhok*1, R. Rao1, S. Honap2, M. Samaan3, L. Harpham-Lockyer3, H. Kwok3, L. Whitley3, A. Ibarra1, N. Burgess1, E. Seward3, G. Parkes1, S. Mehta3, R. Vega3, S. McCartney3, S. Bloom3, P. Irving2, J. O. Lindsay1, K. Kok1, F. Rahman3

1The Royal London Hospital, Barts Health NHS Trust, Department of Gastroenterology, London, UK, 2Guy's and St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, UK, 3University College London Hospitals NHS Foundation Trust, Department of Gastroenterology, London, UK

P319: Trough levels of adalimumab better correlate with combined mucosal and transmural healing than clinical remission in Korean patients with Crohn’s disease on adalimumab maintenance therapy

ECCO '19 Copenhagen

Year: 2019
Authors:

E. H. Oh*1, A-R. Yoon2, S. H. Park3, J. Kim1, N. Ham1, E. M. Song1, S. W. Hwang1,2, S. H. Park1,2, D-H. Yang1, J-S. Byeon1, S-J. Myung1, S-K. Yang1,2, B. D. Ye1,2

1Asan Medical Center, Gastroenterology, Seoul, South Korea, 2Asan Medical Center, Inflammatory Bowel Disease Center, Seoul, South Korea, 3Asan Medical Center, Radiology, Seoul, South Korea

P320: High Cytomegalovirus DNA load in mucosal biopsies predicts steroid failure as well as colectomy in acute severe ulcerative colitis

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Jain1, D. Namdeo1, S. Kedia1, P. Sahu1, P. Das1, P. Sahni1, N. R. Dash1, S. Pal1, G. Makharia1, L. Dar1, V. Ahuja*1

1All India Institute of Medical Sciences, New Delhi, India

P321: On effectiveness, safety, and TDM of thioguanine in a cohort of 274 patients with IBD, intolerant for conventional thiopurines

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Simsek*1, D. Deben2, C. S. Horjus3, M. Seinen1, C. J. Mulder1, D. R. Wong2, N. K. de Boer1, A. A. van Bodegraven4

1Amsterdam UMC, VU Medical Center, Gastroenterology and Hepatology, Amsterdam, The Netherlands, 2Zuyderland Medical Center, Clinical Pharmacy, Sittard-Geleen-Heerlen, The Netherlands, 3Rijnstate Hospital, Gastroenterology and Hepatology, Arnhem, The Netherlands, 4Zuyderland Medical Center, Gastroenterology and Hepatology, Sittard-Geleen-Heerlen, The Netherlands

P322: Disease-related worries and concerns in patients with ulcerative colitis: 1-year data from ICONIC

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Ghosh*1, F. Casellas2, C. O’Shea3, K. Kligys4, J. Petersson4, L. Peyrin-Biroulet5

1University of Birmingham, Birmingham, UK, 2Crohn-Colitis Care Unit (UACC), Hospital Universitari Vall, Vall d'Hebron, Spain, 3AbbVie Ltd., Dublin, Ireland, 4AbbVie Inc., North Chicago, Illinois, USA, 5University of Lorraine, Nancy, France

P323: Prognostic factors for long-term adalimumab treatment

ECCO '19 Copenhagen

Year: 2019
Authors:

M. Fumery*1, N. Duveau2, C. Perignon3, G. Lepeut4, A. Lahaye1, G. Le Baut1, C. Roussillon3, C. Yzet1, J. Loreau1, P. Wils4, M. Nachury4, B. Pariente4, S. Viennot3

1Amiens Hospital, Gastroenterology, Amiens, France, 2Roubaix Hospital, Gastroenterology, Roubaix, France, 3Caen Hospital, Gastroenterology, Caen, France, 4Claude Huriez Hospital, Lille University, Gastoenterology, Lille, France

P324: Tuberculosis infection under anti-TNF therapy – should we be looking for it?

ECCO '19 Copenhagen

Year: 2019
Authors:

S. Xavier*1,2,3, T. Cúrdia Gonçalves1,2,3, F. Dias de Castro1,2,3, J. Magalhães1,2,3, M. J. Moreira1,2,3, J. Cotter1,2,3

1Hospital da Senhora da Oliveira, Guimarães, Gastroenterology, Guimarães, Portugal, 2School of Medicine, University of Minho, Braga, Portugal, 3ICVS/3B’s Associate Laboratory, University of Minho, Braga/Guimarães, Portugal

P325: Integrating efficacy and safety of vedolizumab and other advanced therapies for the treatment of ulcerative colitis: Results from a network meta-analysis

ECCO '19 Copenhagen

Year: 2019
Authors:

V. Jairath*1, K. Lasch2, K. Chan3, S. Kanters4, J. Jansen4, C. Agboton5, H. Patel6

1Western University, London, ON, Canada, 2Takeda Pharmaceuticals International, Deerfield, IL, USA, 3Precision Xtract, Vancouver, BC, Canada, 4Precision Xtract, Oakland, CA, USA, 5Takeda Pharmaceuticals International AG, Zurich, Switzerland, 6Takeda Pharmaceuticals International, Deerfield, USA

P326: Audit and review of infliximab therapeutic drug monitoring and prescribing practices in paediatric inflammatory bowel disease (IBD) patients

ECCO '19 Copenhagen

Year: 2019
Authors:

C. Lang*1

1Our Lady's Children's Hospital Crumlin, Pharmacy, Dublin, Ireland

P327: Segmental colectomy for ulcerative colitis: a new paradigm? A multi-centric study in 72 patients

ECCO '19 Copenhagen

Year: 2019
Authors:

A. Frontali*1, Y. Panis1, L. Cohen2, V. Bridoux3, P. Myrelid4, G. Sica5, G. Poggioli6, E. Espin7, L. Beyer-Berjot8, D. Laharie9, A. Spinelli10, P. Zerbib11, G. Sampietro12, M. Frasson13, E. Louis14, X. Treton2

1Beaujon Hospital, Colorectal Surgery, Clichy, France, 2Beaujon Hospital, Gastroenterology, Clichy, France, 3CHU Rouen, Digestive Surgery, Rouen, France, 4Linkoping Hospital, Digestive Surgery, Linkoping, Sweden, 5Policlinico Tor Vergata, Digestive Surgery, Roma, Italy, 6Policlinico Sant'Orsola-Malpighi, Digestive Surgery, Bologna, Italy, 7Hospital Universitari Val d'Hebron, Digestive Surgery, Barcelona, Spain, 8Hôpital Nord, Digestive Surgery, Marseille, France, 9CHU Bordeaux, Gastroenterology, Bordeaux, France, 10Humanitas Research Hospital, Colorectal Surgery, Rozzano - Milano, Italy, 11CHU Lille, Digestive Surgery, Lille, France, 12Ospedale L. Sacco, Chirurgia Generale 2, Milano, Italy, 13University Hospital La Fe, Digestive Surgery, Valencia, Spain, 14CHU Liege, Gastroenterology, Liege, France

P328: Low vitamin K, vitamin D and calcium dietary intake in IBD patients represents a potentially reversible risk factor for osteoporosis

ECCO '19 Copenhagen

Year: 2019
Authors:

N. S. Bertetti1, G. Burrelli Scotti1, M. T. Afferri1, V. Casali1, E. Cuofano1, C. Tortoriello1, A. De Carolis1, P. Vernia*1

1Sapienza University of Rome, Department of Internal Medicine and Medical Specialties, Gastroenterology, Rome, Italy

P329: Adalimumab therapeutic drug monitoring test validated for measuring ABP 501 biosimilar

ECCO '19 Copenhagen

Year: 2019
Authors:

M. B. Ruiz-Argüello1, A. Maguregui1, A. Martínez1, D. Nagore1

1Progenika Biopharma-Grifols, Derio, Spain

P330: A national survey on therapeutic education in inflammatory bowel disease by an association of caregivers and expert patients: French Association for Therapeutic Education in inflammatory bowel disease (AFEMI)

ECCO '19 Copenhagen

Year: 2019
Authors:

J. Moreau1, E. Balez2, C. Devos3, X. Hébuterne4, M. Veltin5, M. Allez*6

1Rangueil Hospital and University, Gastroenterology, Toulouse, France, 2Afa Crohn RCH France, Nice, France, 3Afa Crohn RCH France, Paris, France, 4Nice Hospital and University, Gastroenterology, Nice, France, 5Nancy Brabois Regional University Hospital, Vandœuvre-lès-Nancy, France, 6Saint-Louis Hospital, Gastroenterology, Paris, France

P331: Real-world assessment of biological treatment of inflammatory bowel disease at an Austrian Referral Centre: the ULTIMATE study

ECCO '19 Copenhagen

Year: 2019
Authors:

H. P. Gröchenig*1, E. Walter2, A. Redl3, M. Bresztowanszky1, K. Steidl1, F. Siebert1, G. Novacek5

1Krankenhaus der Barmherzigen Brüder, Internal Medicine, St. Veit an der Glan, Austria, 2Institute for Pharmaeconomic Research, Vienna, Austria, 3Datamedrix GmbH, Vienna, Austria, 5Medical University of Vienna, Department of Internal Medicine III, Division of Gastroenterology and Hepatology, Vienna, Austria